Ischemic stroke and reperfusion are associated with an inflammatory response characterized in part by the formation of leukocyte-platelet aggregates (LPAs). Aggregate formation may enhance the immune and hemostatic functions of both cell types, thereby exacerbating reperfusion injury after ischemic stroke. The formation of LPAs in peripheral blood may also serve as a biomarker of injury severity. Using in vivo fluorescence microscopy in an animal model of focal ischemic stroke, researchers directly observed LPAs adhering to the cerebral microcirculation in response to systemic blood activation or ischemic events. LPA formation may be a useful biomarker and potential therapeutic target after ischemic stroke and reperfusion.
Fig. 1. Methods to investigate leukocyte-platelet-aggregate formation. (Finsterbusch et al., 2018)
Ace Therapeutics can measure LPAs in animal stroke models in different (pathologic) physiological settings. Our professional staff provides comprehensive assistance in experimental design, animal study protocols, animal handling, in vivo imaging, and data analysis.
We offer a range of tools to monitor leukocyte and platelet adhesion after ischemia and reperfusion. Here you can obtain information on the location of LPAs within brain tissue, the dynamics of their interactions and/or dynamic changes in leukocyte and platelet behavior.
We can quantify circulating LPAs in the blood of stroke animals and investigate the expression of related molecules by conventional flow cytometry (CFC).
Sample | Small amount (~ 5 μL) of whole blood |
---|---|
Advantages and Features |
|
Markers | CD45 (pan-leukocyte marker), Ly6G (neutrophil marker), CD11b (marker for cells other than lymphocytes), and CD41 (pan-platelet marker). |
Display of Results | The amounts of LPAs can be displayed as the percentage of leukocytes (or their subsets) bound to platelets or as the percentage of platelet aggregates containing leukocytes. |
We also offer imaging flow cytometry (IFC) to determine LPAs. LPAs allow for a more efficient differentiation between platelets and leukocytes in close proximity than CFC. More importantly, IFC enables higher throughput without significantly over-detecting LPAs.
We use light microscopy to assess LPAs quantitatively and qualitatively in brain tissues of stroke animals.
Samples | Brain tissue sections |
---|---|
Advantages and Features |
|
We offer stroke researchers the opportunity to perform high-resolution imaging of the real-time dynamics of platelet-leukocyte interactions in live animal models. Our state-of-the-art microscopy facilities and microscopes are accessible to the region of interest.
Samples | Live animals |
---|---|
Advantages and Features |
|
Our LPA assessment service allows us to assist clients in:
LPAs are particularly sensitive parameters reflecting the process of thrombosis and inflammation after stroke. Ace Therapeutics's LPA measurement service can provide an attractive and easy-to-use prognostic and/or diagnostic tool for preclinical stroke research. If you are interested in our services, please do not hesitate to contact us!
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.